| __timestamp | HUTCHMED (China) Limited | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 72471000 |
| Thursday, January 1, 2015 | 29829000 | 89204000 |
| Friday, January 1, 2016 | 39578000 | 106010000 |
| Sunday, January 1, 2017 | 43277000 | 137905000 |
| Monday, January 1, 2018 | 48645000 | 159888000 |
| Tuesday, January 1, 2019 | 52934000 | 158425000 |
| Wednesday, January 1, 2020 | 61349000 | 200677000 |
| Friday, January 1, 2021 | 127125000 | 304759000 |
| Saturday, January 1, 2022 | 136106000 | 377221000 |
| Sunday, January 1, 2023 | 133175999 | 336361000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of HUTCHMED (China) Limited and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Supernus Pharmaceuticals consistently outpaced HUTCHMED in SG&A spending, with a peak in 2022 where their expenses were nearly three times higher. Notably, HUTCHMED's SG&A expenses grew by approximately 400% from 2014 to 2023, reflecting their strategic investments in market expansion and operational efficiency. Meanwhile, Supernus saw a more than 360% increase, underscoring their aggressive market penetration and product development strategies. This financial trajectory highlights the contrasting approaches of these two companies in navigating the competitive pharmaceutical industry. As we move forward, these trends offer valuable insights into their future growth and market positioning.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.